MedPath

EUGIA PHARMA (AUSTRALIA) PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

54

TGA:54

Drug Approvals

IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial (439214)

Product Name
IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial (439216)

Product Name
IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

EUG-IRINOTECAN irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial (439201)

Product Name
EUG-IRINOTECAN irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

EUG-IRINOTECAN irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial (439199)

Product Name
EUG-IRINOTECAN irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

IRINOTECAN EPSL irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial (439212)

Product Name
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial (439213)

Product Name
IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

IRINOTECAN EPSL irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial (439203)

Product Name
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

EUG-IRINOTECAN irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial (439202)

Product Name
EUG-IRINOTECAN irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

IRINOTECAN EPSL irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial (439210)

Product Name
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA

IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial (439215)

Product Name
IRINOTECAN EUGIA irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial
Approval Date
Mar 17, 2025
TGA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.